Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Mr. McCann has Board experience with some of Australia's companies. He is a former corporate lawyer and experienced Chairman and Director of listed private and government companies, and government agencies. In his roles as Chairman of the Board and Chair of the People, Culture, Nomination and Remuneration Committee, his experienced leadership promotes a cohesive, constructive challenge and oversight environment. Mr. McCann's expertise in shaping culture (including through organizational and remuneration design), public policy, social performance and stakeholder engagement, enables him to bring insights in these areas. Previously, Mr. McCann served as Chairman of Macquarie Group and Macquarie Bank Limited (from December 1996 to March 2016), Chairman of Origin Energy Limited from (January 2000 to October 2013), Chairman of the Sydney Harbour Federation Trust (from June 2001 to June 2010 and from June 2015 to June 2018), Director of Bluescope Steel Ltd from (May 2002 to April 2013), Director of E&P Financial Group Ltd (from February 2020 to November 2021) and Chairman of China Matters (from November 2018 to December 2023). He was also a Director of the United States Studies Centre at the University of Sydney (from June 2010 to June 2020) and was a Trustee of the Sydney Opera House (from January 2018 to December 2023). He has served as a Member of Champions of Change Founding Group (since April 2010), Chairman of Sydney Harbour Foundation Management (since August 2015), Director of Australian Haydn Ensemble (since December 2020), Chair and Board Advisor of Blueprint Institute (since June 2022) and Director of Billard Leece Partnership Pty Limited (since October 2024). Mr. McCann practised as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He was made an Officer of the Order of Australia for services to business, corporate governance and gender equality in January 2020. He is member of Risk Commitee and chair of Disclosure Commitee and People and Culture Committee.

Ms. Skinner has financial acumen, accounting and auditing expertise, with understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively. Ms. Skinner has experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She has served as a Director of Create Foundation Limited (since June 2004). She previously also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023) and as an independent Non-Executive Director of QBE Insurance Group Limited (from October 2014 to May 2024). She is chair of Risk Commitee and member of People, Culture Committee and Disclosure Commitee.

Ms McDonald is a Director of several ASX-listed life science companies including CSL and Nanosonics. She brings experience in financial markets, mergers and acquisitions, regulatory policy, remuneration, risk management and compliance. Ms McDonald practised for 30 years as a commercial lawyer for law firm Ashurst Australia and was previously a long-serving member of the Australia Takeovers Panel.

Dr. Behrenbruch has more than two decades of radiopharmaceuticals experience and a track record in global healthcare and biotechnology entrepreneurship and technology commercialization. He brings a blend of technical expertise and executive leadership to guide Telix as it enters the next stage of its strategy. Dr. Behrenbruch has a focus on purpose and values-leadership, and is versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia. Previously, Dr. Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011). Dr. Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014). He is member of Disclosure Commitee.

Dr. Nelson's experience in the investment community, including in life sciences, brings a sound investment perspective to the implementation of Telix's strategy. Dr. Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr. Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005). He is member of risk committee and People and Culture Committee.

Ms. Olson brings experience in commercialization and corporate strategy in oncology, including in the radiopharmaceuticals sector, which the Telix Board values as it oversees the implementation of the Company's strategy. Ms. Olson's most recent executive role was with Cardinal Health, the provider of radiopharmaceuticals in the U.S.. As President of Cardinal Health Nuclear & Precision Health Solutions (from July 2013 to October 2021), overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network, she led a business transformation that increased market share and profit growth. Prior to Cardinal Health, Ms. Olson served as President of NaviMed (from August 2011 to July 2013), as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and at BioTelemetry, Inc. (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc. (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022), a Partner at Trusted Health Advisors (since August 2023) and Director of MiMedx Group, Inc. (since March 2024). She is member of risk committee and People and Culture Committee.

Ms Whitaker is a healthcare leader and advisor with over 30 years global corporate experience spanning pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms Whitaker is currently serving as a NED at Icon PLC (NASDAQ: ICLR) and is Chair at QurAlis Corporation. Ms. Whitaker is an Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline (GSK), Sanofi and Bausch Health.

-

-

-

-

-

-

-

-

-

-